Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc (NQ: COSM )

0.6500 UNCHANGED
Streaming Delayed Price Updated: 3:45 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.6500
Bid (Size) 0.6500 (3)
Ask (Size) 0.6800 (39)
Prev. Close 0.6500
Today's Range 0.6500 - 0.6500
52wk Range 0.4677 - 3.450
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q
Via ACCESSWIRE

Performance

YTD
-52.55%
-52.55%
1 Month
-7.10%
-7.10%
3 Month
-14.70%
-14.70%
6 Month
-38.10%
-38.10%
1 Year
-80.83%
-80.83%

More News

Read More
Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand
Via ACCESSWIRE
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Healthcare Stocks
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
Via ACCESSWIRE
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
Via ACCESSWIRE
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
Via ACCESSWIRE
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
Via ACCESSWIRE
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
Via ACCESSWIRE
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
Via ACCESSWIRE
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Taglich Brothers Initiates Coverage of Cosmos Health Inc.
Via ACCESSWIRE
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
Via ACCESSWIRE
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
Via ACCESSWIRE
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
Via ACCESSWIRE
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
Via ACCESSWIRE
Cosmos Health Announces Open Market Stock Purchases by the CEO
Via ACCESSWIRE
Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York
Via ACCESSWIRE
Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers
Via ACCESSWIRE
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
Via ACCESSWIRE
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
Via ACCESSWIRE
Over $5M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.